Sharda Cropchem FY26 Revenue Surges 22% to ₹5,268 Crore, PAT Jumps 124%
Sharda Cropchem reported FY26 revenue of ₹5,268 crore, a 22% increase YoY, with PAT soaring 124% to ₹681 crore. Q4 FY26 revenue rose 13% to ₹2,065 crore, and PAT grew 57% to ₹319 crore. Gross margins improved significantly, and EBITDA jumped 69% for the full year. The company plans to focus on sales force expansion and operational efficiencies.
The substantial increase in revenue and profit, coupled with record-high PAT and strong margin improvements, is a material positive development for the company, likely to be viewed favorably by investors.
The company reported strong year-on-year growth in revenue, significant improvements in profitability (EBITDA and PAT), and an all-time high PAT. The outlook and strategic focus areas also appear positive.
Sharda Cropchem Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a significant 13% increase in total revenues for the fourth quarter of FY26, reaching ₹2,065 crore, driven by a 4.3% volume growth and a favorable product mix, particularly in the Europe and LATAM regions. The agrochemical segment saw a 14% revenue jump to ₹1,927 crore, with volumes growing by 4.5%. The non-agrochemical segment, however, experienced a slight de-growth of 2.3% in volumes, with revenues remaining stable at ₹138 crore.
For the full fiscal year FY26, Sharda Cropchem's total revenues grew by 22% to ₹5,268 crore, propelled by a sustained volume growth of over 13%. The agrochemical segment revenue increased by 25% to ₹4,717 crore, with volumes up by 13.3%. The non-agrochemical segment also saw a positive growth of 15.3% in volumes, contributing ₹551 crore in revenue.
The company demonstrated strong improvements in profitability. Gross Margins expanded by 750 basis points to 37.3% in Q4 FY26 and by 600 basis points to 35.9% for the full year FY26. EBITDA for the quarter surged by 75% to ₹513 crore, with EBITDA margins at 24.8%. Full-year EBITDA grew by 69% to ₹1,040 crore, with margins at 19.7%.
Profit After Tax (PAT) for the fourth quarter of FY26 more than doubled, increasing by 57% to ₹319 crore, compared to ₹204 crore in the prior year. For the full fiscal year, PAT reached an all-time high of ₹681 crore, a substantial 124% increase from ₹304 crore in FY25. Earnings Per Share (EPS) for FY26 stood at ₹75.47, up from ₹33.74 in FY25.
Sharda Cropchem also highlighted a strong balance sheet, with total equity growing to ₹3,137 crore as of March 2026. The company managed to reduce its working capital by 20 days. Return on Capital Employed (RoCE) stood at 30.4% and Return on Equity (RoE) at 24.2% as of March 31, 2026.
The company is focused on forward integration by building its sales force, expanding its distribution presence, continually investing in product registrations, and focusing on operational efficiencies for margin improvements and cost management.
What to do with a filing like this
Sharda Cropchem Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sharda Cropchem Limited. Read the original for the full detail.